血浆生物标志物策略用于筛选适合抗淀粉样蛋白免疫治疗的阿尔茨海默病患者
本研究为BioFINDER-2前瞻性队列研究,纳入912名有认知担忧的参与者,评估血浆生物标志物识别Aβ阳性及tau积累阶段的能力。血浆p-tau217在测试集中识别Aβ阳性的AUC为0.94,采用双切点流程可使17.1%的测试集参与者接受确证性检查,总体灵敏度0.94、特异度0.86;在Aβ阳性者中区分高tau负荷的AUC为0.92,在假阴性率低于10%时可避免56.9%的tau-PET扫描。作者认为血浆p-tau217算法可准确识别多数Aβ阳性个体,可能大幅减少确证性检查数量。
要点
- 血浆p-tau217识别Aβ阳性的测试集AUC为0.94(95%CI 0.90-0.97)。
- 双切点流程仅17.1%测试集参与者需CSF或PET确证,灵敏度0.94、特异度0.86。
- 血浆p-tau217区分Aβ阳性者高tau负荷的AUC为0.92,假阴性率低于10%时可避免56.9%的tau-PET扫描。
核心结论
- 使用血浆p-tau217的算法能准确识别大多数Aβ阳性个体,包括可能需要确证性tau-PET成像的高tau负荷者。
- 血浆p-tau217检测可能大幅减少识别可能受益于抗淀粉样蛋白治疗者所需的侵入性且昂贵的确证性检查数量。
研究设计与样本
- BioFINDER-2为前瞻性记忆门诊和人群队列研究,2017年至2022年招募有认知担忧的参与者。
- 共纳入912名参与者,其中男性499名(54.7%)、女性413名(45.3%),平均(SD)年龄71.1(8.49)岁。
- 参与者被分为训练集(数据的80%)和测试集(数据的20%)。
- 基线暴露包括血浆p-tau181、p-tau217、p-tau231、N端tau、胶质纤维酸性蛋白和神经丝轻链。
- 结果在独立队列(n=118)中得到验证。
主要发现
- 血浆p-tau217与Aβ阳性关联最强,测试集AUC=0.94(95%CI 0.90-0.97)。
- 双切点流程中仅血浆p-tau217值不确定的参与者(测试集的17.1%)接受CSF或PET以确定Aβ状态,总体灵敏度0.94(95%CI 0.90-0.98)、特异度0.86(95%CI 0.77-0.95)。
- 在Aβ阳性参与者中区分低-中等与高tau-PET负荷时,血浆p-tau217表现最佳,测试集AUC=0.92(95%CI 0.86-0.97),加入其他血浆生物标志物未见显著改善。
- 在假阴性率低于10%时,使用血浆p-tau217可避免识别Aβ阳性参与者中高tau-PET所需tau-PET扫描的56.9%。
关键数值与推荐
- Aβ状态由Aβ-PET或CSF Aβ42/40定义,tau状态由tau-PET定义。
- 血浆p-tau217识别Aβ阳性的测试集AUC=0.94(95%CI 0.90-0.97)。
- 双切点流程的总体灵敏度0.94(95%CI 0.90-0.98)、特异度0.86(95%CI 0.77-0.95),仅17.1%测试集参与者需CSF或PET确证。
- 血浆p-tau217区分Aβ阳性者高tau负荷的测试集AUC=0.92(95%CI 0.86-0.97)。
- 假阴性率低于10%时,血浆p-tau217可避免56.9%的tau-PET扫描。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging. Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)-positive patients without an advanced stage of tau pathology who are most likely to benefit from these therapies. Blood-based biomarkers might reduce the need to use cerebrospinal fluid (CSF) or positron emission tomography (PET) for this. OBJECTIVE: To evaluate plasma biomarkers for identifying Aβ positivity and stage of tau accumulation. DESIGN, SETTING, AND PARTICIPANTS: The cohort study (BioFINDER-2) was a prospective memory-clinic and population-based study. Participants with cognitive concerns were recruited from 2017 to 2022 and divided into a training set (80% of the data) and test set (20%). EXPOSURE: Baseline values for plasma phosphorylated tau 181 (p-tau181), p-tau217, p-tau231, N-terminal tau, glial fibrillary acidic protein, and neurofilament light chain. MAIN OUTCOMES AND MEASURES: Performance to classify participants by Aβ status (defined by Aβ-PET or CSF Aβ42/40) and tau status (tau PET). Number of hypothetically saved PET scans in a plasma biomarker-guided workflow. RESULTS: Of a total 912 participants, there were 499 males (54.7%) and 413 females (45.3%), and the mean (SD) age was 71.1 (8.49) years. Among the biomarkers, plasma p-tau217 was most strongly associated with Aβ positivity (test-set area under the receiver operating characteristic curve [AUC] = 0.94; 95% CI, 0.90-0.97). A 2-cut-point procedure was evaluated, where only participants with ambiguous plasma p-tau217 values (17.1% of the participants in the test set) underwent CSF or PET to assign definitive Aβ status. This procedure had an overall sensitivity of 0.94 (95% CI, 0.90-0.98) and a specificity of 0.86 (95% CI, 0.77-0.95). Next, plasma biomarkers were used to differentiate low-intermediate vs high tau-PET load among Aβ-positive participants. Plasma p-tau217 again performed best, with the test AUC = 0.92 (95% CI, 0.86-0.97), without significant improvement when adding any of the other plasma biomarkers. At a false-negative rate less than 10%, the use of plasma p-tau217 could avoid 56.9% of tau-PET scans needed to identify high tau PET among Aβ-positive participants. The results were validated in an independent cohort (n = 118). CONCLUSIONS AND RELEVANCE: This study found that algorithms using plasma p-tau217 can accurately identify most Aβ-positive individuals, including those likely to have a high tau load who would require confirmatory tau-PET imaging. Plasma p-tau217 measurements may substantially reduce the number of invasive and costly confirmatory tests required to identify individuals who would likely benefit from antiamyloid therapies.
引用
- Mattsson-Carlgren N, Collij LE, Stomrud E, et al. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurol. 2024. PMID: 38048096. doi:10.1001/jamaneurol.2023.4596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。